Evidence map›Paper›PMID 28181176›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2017

Circulating levels of autoantibodies against L1-cell adhesion molecule as a potential diagnostic biomarker in esophageal squamous cell carcinoma.

Y-W Xu, Y-H Peng, L-Q Ran, T-T Zhai, H-P Guo, S-Q Qiu, H-L Chen, Z-Y Wu, E-M Li, J-J Xie

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Y-W XuDepartment of Clinical Laboratory Medicine, The Cancer Hospital of Shantou University Medical College, Shantou, China.
Y-H PengDepartment of Clinical Laboratory Medicine, The Cancer Hospital of Shantou University Medical College, Shantou, China.
L-Q RanDepartment of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou, China.
T-T ZhaiDepartment of Radiation Oncology, The Cancer Hospital of Shantou University Medical College, Shantou, China.
H-P GuoDepartment of Head and Neck Surgery, The Cancer Hospital of Shantou University Medical College, Shantou, China.
S-Q QiuThe Breast Center, The Cancer Hospital of Shantou University Medical College, Shantou, China.
H-L ChenDepartment of Surgical Oncology, Shantou Central Hospital, Shantou, China.
Z-Y WuDepartment of Surgical Oncology, Shantou Central Hospital, Shantou, China.
E-M LiThe Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou, China. nmli@stu.edu.cn.
J-J XieThe Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou, China. g_jjxie@stu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEsophageal squamous cell carcinoma (ESCC) is a common malignant disease worldwide, especially in China. We aimed to determine the level of autoantibodies against L1CAM in patients with ESCC.

methodsLevels of circulating autoantibodies against L1CAM antigens were determined by an enzyme-linked immunosorbent assay in cohort 1 (191 patients with ESCC and 94 normal controls) and validated in cohort 2 (47 patients with ESCC and 47 normal controls). Receiver-operating characteristics were employed to calculate diagnostic accuracy. Cumulative survival time was calculated by the Kaplan-Meier method and analyzed by the log-rank test.

resultsIn cohorts 1 and 2, levels of autoantibodies against L1CAM were all significantly higher in sera of patients with ESCC compared to normal controls (P < 0.05). Detection of autoantibodies against L1CAM provided a sensitivity of 26.2%, a specificity of 90.4%, and an area under the curve (AUC) of 0.603 (95% CI 0.535-0.672) in diagnosing ESCC in cohort 1, and a sensitivity of 27.7%, a specificity of 91.5%, and an AUC of 0.628 (95% CI 0.516-0.741). Similar results were observed in the diagnosis of early stage ESCC (25.2% sensitivity, 90.4% specificity, and an AUC of 0.611 (95% CI 0.533-0.689) in cohort 1, and 33.3% sensitivity, 91.5% specificity, and an AUC of 0.636 (95% CI 0.439-0.832) in cohort 2). Moreover, positive rates of autoantibodies against L1CAM had no statistical correlation with clinical outcome of ESCC (P > 0.05).

conclusionsOur results suggest that circulating autoantibodies against L1CAM is a potential biomarker for the early detection of ESCC.

Indexed as

AdultAgedAged, 80 and overAutoantibodiesBiomarkers, TumorCarcinoma, Squamous CellCase-Control StudiesCombined Modality TherapyEsophageal NeoplasmsFemaleFollow-Up StudiesHumansLymphatic MetastasisMaleMiddle AgedNeoplasm InvasivenessAutoantibodiesBiomarkers, TumorNeural Cell Adhesion Molecule L1AutoantibodiesDiagnosisEsophageal squamous cell carcinomaL1CAMSera

Identifiers

PMID28181176

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.